ACTU (Actuate Therapeutics) Beginning Cash Position: $13.16 Mil (As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.51
View Full Analysis

What is Actuate Therapeutics Beginning Cash Position?

Actuate Therapeutics ACTU +6.29% 14 Beginning Cash Position is $13.16 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $13.16 Mil.

Actuate Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($6.49 Mil) to Dec. 2025 ($16.92 Mil) but then declined from Dec. 2025 ($16.92 Mil) to Mar. 2026 ($13.16 Mil).

Actuate Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($20.45 Mil) to Dec. 2024 ($2.96 Mil) but then increased from Dec. 2024 ($2.96 Mil) to Dec. 2025 ($8.64 Mil).

Actuate Therapeutics Beginning Cash Position Related Terms

Actuate Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Beginning Cash Position Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
18.99 20.45 2.96 8.64

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.64 3.89 6.49 16.92 13.16
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $13.16 Mil mean?
Actuate Therapeutics (ACTU) has a Beginning Cash Position of $13.16 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Beginning Cash Position too high?
Actuate Therapeutics' current Beginning Cash Position is $13.16 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Beginning Cash Position compare to RNXT and ESLA?
Actuate Therapeutics' Beginning Cash Position of $13.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Beginning Cash Position is $13.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Beginning Cash Position of $13.16 Mil. The current Beginning Cash Position is $13.16 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Beginning Cash Position is $13.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.51
Price